Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. Co. is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. Co. has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. The MNPR average annual return since 2019 is shown above.
The Average Annual Return on the MNPR average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MNPR average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MNPR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free MNPR Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
